Table 2. Change in serum biomarkers for 34 subjects who completed the trial.

Biomarker	Median prestudy	Median poststudy	Median absolute change	Median relative change	P (Wilcoxon)
ELISA methodology
High-molecular weight adiponectin, μg/mL	5.8	5.7	−0.09	−2%	0.73
hsCRP, μg/mL	1.4	1.2	−0.2	−23%	0.16
IGFI, nmol/L	18.5	16.7	0.4	3%	0.98
IGFBP3, nmol/L	116	110	−4	−4%	0.080
IGF-1:IGFBP3 ratio	0.16	0.17	0.01	5%	0.20
SHBG, nmol/L (with estradiol)	114.5	112.6	2.5	5%	0.33
Estradiol, pg/mL	73.3	77.4	−10.5	−11%	0.13
Estradiol, pmol/L	0.27	0.29	−0.4	−11%
Bioavailable estradiol, pmol/L	2.71	3.08	−0.31	−15%	0.13
Progesterone, ng/mL	0.90	0.97	−0.03	−4%	0.98
Progesterone, nmol/L	2.9	3.1	−0.1	−4%
SHBG, nmol/L (with testosterone)	99.4	105.5	0.6	1%	0.86
Testosterone, ng/mL	0.55	0.46	−0.03	−5%	0.38
Testosterone, nmol/L	1.88	1.60	−0.11	−5%
Bioavailable testosterone, pmol/L	16.6	16.5	−0.12	−2%	0.38
Luminex methodology
Adiponectin, μg/mL	17.0	18.4	−1.3	−8%	0.44
Leptin, ng/mL	12.3	12.3	1.2	9.4%	0.67
Adipo:Leptin ratio	1,170	1,559	−36	−6%	0.37
HGF, pg/mL	264	240	−17	−8%	0.74
Insulin, pg/mL	168	140	−18	−9%	0.22
MCP-1, pg/mL	179	166	−7	−5%	0.21
NGF, pg/mL	5.9	5.5	−0.3	−6%	0.18
PAI-1, ng/mL	30.3	32.1	−0.8	−3%	0.97
Resistin, ng/mL	23.4	24.5	−0.8	−4%	0.54
TNF-α, pg/mL	2.7	2.8	0.0	0%	0.88
Assessment of insulin resistance
Glucose, mg/dL	95.0	93.0	−2.5	−3%	0.075
Immunoreactive Insulin, μIU/ml	5.3	4.7	0.0	0%	0.55
Pro-Insulin, pmol/L	8.7	9.2	0.2	2%	0.89
HOMA2 %B	61.2	66.7	5.1	9%	0.13
HOMA2 %S	142.6	160.3	−0.1	0%	0.78
HOMA2 IR	0.7	0.6	0.0	0%	0.32